UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 138

Sortiert nach

Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease

European journal of neurology, 2013-02, Vol.20 (2), p.271-280

2013

Link zum Volltext

Verfügbarkeit prüfen

Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations

Movement disorders, 2014-02, Vol.29 (2), p.229-237

2014

Link zum Volltext

Verfügbarkeit prüfen

Evenamide, as an add-on to antipsychotics, benefits patients with treatment resistant schizophrenia: 6-month interim results from the first 100 patients in an ongoing international randomized study

European psychiatry, 2023-03, Vol.66 (S1), p.S639-S639

2023

Link zum Volltext

Verfügbarkeit prüfen

Different physiological and behavioural effects of e-cigarette vapour and cigarette smoke in mice

European neuropsychopharmacology, 2015-10, Vol.25 (10), p.1775-1786

2015

Link zum Volltext

Verfügbarkeit prüfen

Feedback dose alteration significantly affects probability of pathogen eradication in nosocomial pneumonia

The European respiratory journal, 2009-08, Vol.34 (2), p.394-400

2009

Link zum Volltext

Verfügbarkeit prüfen

Long-term efficacy of safinamide as add-on to levodopa in Parkinson’s disease fluctuating patients: results from a 2-year placebo-controlled trial

Journal of the neurological sciences, 2015-10, Vol.357, p.e276-e276

2015

Link zum Volltext

Verfügbarkeit prüfen

Safinamide is effective as add-on treatment in both early and Advanced PD

Journal of the neurological sciences, 2013-10, Vol.333, p.e69-e69

2013

Link zum Volltext

Verfügbarkeit prüfen

Comparison of the potency of 10 different brands of Serenoa repens extracts

European review for medical and pharmacological sciences, 2012-05, Vol.16 (5), p.569

2012

Link zum Volltext

Verfügbarkeit prüfen

Role of Hsp70 in lung inflammation after chronic stress

Brain, behavior, and immunity, 2011, Vol.25, p.S192-S192

2011

Link zum Volltext

Verfügbarkeit prüfen

Strenuous physical stress increases risk of respiratory tract infection (RTI)

Brain, behavior, and immunity, 2010, Vol.24, p.S20-S20

2010

Link zum Volltext

Verfügbarkeit prüfen

2.268 FIRST 2-YEAR, PLACEBO-CONTROLLED STUDY IN PARKINSON'S DISEASE PATIENTS WITH MOTOR FLUCTUATIONS INDICATES SAFINAMIDE MAY BENEFIT PATIENTS WITH MORE SEVERE DYSKINESIA

Parkinsonism & related disorders, 2012, Vol.18, p.S132-S133

2012

Link zum Volltext

Verfügbarkeit prüfen

2.267 LONG-TERM EFFICACY OF SAFINAMIDE AS ADD-ON TO LEVODOPA IN PARKINSON'S DISEASE (PD) USING AN ‘ON’ AND ‘ON-OFF’ TREATMENT ANALYSIS

Parkinsonism & related disorders, 2012, Vol.18, p.S132-S132

2012

Link zum Volltext

Verfügbarkeit prüfen

2.266 TWO-YEAR, PLACEBO-CONTROLLED SAFETY AND TOLERABILITY DATA FOR SAFINAMIDE AS ADD-ON TO LEVODOPA IN PATIENTS WITH PARKINSON'S DISEASE (PD)

Parkinsonism & related disorders, 2012, Vol.18, p.S132-S132

2012

Link zum Volltext

Verfügbarkeit prüfen

2.269 SAFINAMIDE AS ADD-ON TO LEVODOPA IN PARKINSON'S DISEASE WITH MOTOR FLUCTUATIONS MAY IMPROVE RESPONDER RATES VERSUS PLACEBO DURING LONG-TERM TREATMENT

Parkinsonism & related disorders, 2012, Vol.18, p.S133-S133

2012

Link zum Volltext

Verfügbarkeit prüfen

P8 Pharmacokinetic/Pharmacodynamics of azithromycin single dose vs three daily doses in a S. pneumoniae or H. influenzae pneumonia model in mice

International journal of antimicrobial agents, 2009, Vol.34, p.S29-S30

2009

Link zum Volltext

Verfügbarkeit prüfen

2-N-Acylaminoalkylindoles: Design and Quantitative Structure−Activity Relationship Studies Leading to MT2-Selective Melatonin Antagonists

Journal of medicinal chemistry, 2001-08, Vol.44 (18), p.2900-2912

2001

Link zum Volltext

Verfügbarkeit prüfen

P2.098 Saflnamide as an adjunct to levodopa signiflcantly improved motor fluctuations in Parkinson's disease: a phase III, randomized, double-blind, placebo-controlled study

Parkinsonism & related disorders, 2009, Vol.15, p.S115-S115

2009

Link zum Volltext

Verfügbarkeit prüfen

P2.108 Improvements in symptom severity and daily living with saflnamide in Parkinson's disease: a phase III, randomized, double-blind, placebo-controlled study

Parkinsonism & related disorders, 2009, Vol.15, p.S118-S118

2009

Link zum Volltext

Verfügbarkeit prüfen

2.209 Long-term double-blind, placebo-controlled evaluation of the safety and efficacy of safinamide as an add-on to stable dopamine agonist therapy in patients with Parkinson's disease

Parkinsonism & related disorders, 2007, Vol.13, p.S99-S100

2007

Link zum Volltext

Verfügbarkeit prüfen

Twenty-Four-Hour Melatonin and Cortisol Plasma Levels in Relation to Timing of Cluster Headache

Cephalalgia, 1995-06, Vol.15 (3), p.224-229

1995

Link zum Volltext

Verfügbarkeit prüfen

Decrease in plasma phenylalanine and tyrosine after phenylalanine-tyrosine free amino acid solutions in man

Life sciences (1973), 1996-05, Vol.58 (26), p.2389-2395

1996

Link zum Volltext

Verfügbarkeit prüfen

Abnormal 24-hour urinary excretory pattern of 6-sulphatoxymelatonin in both phases of cluster headache

Cephalalgia, 1998-12, Vol.18 (10), p.664-667

1998

Link zum Volltext

Verfügbarkeit prüfen

Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo

Cancer research (Chicago, Ill.), 2001-10, Vol.61 (20), p.7501-7506

2001

Link zum Volltext

Verfügbarkeit prüfen

Autoradiographic localization of putative melatonin receptors in the brains of two Old World primates: Cercopithecus aethiops and Papio ursinus

Neuroscience, 1993, Vol.52 (2), p.459-468

1993

Link zum Volltext

Verfügbarkeit prüfen

Long‐term efficacy and safety of safinamide as add‐on therapy in early P arkinson's disease

European journal of neurology, 2013-02, Vol.20 (2), p.271-280

2013

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 138

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(127)
Mit Volltextzugriff
(123)

Publikationsform

Artikel
(136)
Tagungsberichte
(2)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(70)
Life Sciences & Biomedicine
(66)
Biological And Medical Sciences
(56)
Male
(53)
Animals
(43)
Humans
(42)
Female
(31)
Medical Sciences
(29)
Fundamental And Applied Biological Sciences. Psychology
(27)
Adult
(26)
Middle Aged
(21)
Receptors, Melatonin
(21)
Neurosciences & Neurology
(20)
Melatonin - Analogs & Derivatives
(18)
Pharmacology. Drug Treatments
(17)
Neurosciences
(16)
Melatonin - Metabolism
(15)
Pharmacology & Pharmacy
(14)
Aged
(13)
Melatonin
(13)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease

Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations

Evenamide, as an add-on to antipsychotics, benefits patients with treatment resistant schizophrenia: 6-month interim results from the first 100 patients in an ongoing international randomized study

Different physiological and behavioural effects of e-cigarette vapour and cigarette smoke in mice

Feedback dose alteration significantly affects probability of pathogen eradication in nosocomial pneumonia

Long-term efficacy of safinamide as add-on to levodopa in Parkinson’s disease fluctuating patients: results from a 2-year placebo-controlled trial

Safinamide is effective as add-on treatment in both early and Advanced PD

Comparison of the potency of 10 different brands of Serenoa repens extracts

Role of Hsp70 in lung inflammation after chronic stress

Strenuous physical stress increases risk of respiratory tract infection (RTI)

2.268 FIRST 2-YEAR, PLACEBO-CONTROLLED STUDY IN PARKINSON'S DISEASE PATIENTS WITH MOTOR FLUCTUATIONS INDICATES SAFINAMIDE MAY BENEFIT PATIENTS WITH MORE SEVERE DYSKINESIA

2.267 LONG-TERM EFFICACY OF SAFINAMIDE AS ADD-ON TO LEVODOPA IN PARKINSON'S DISEASE (PD) USING AN ‘ON’ AND ‘ON-OFF’ TREATMENT ANALYSIS

2.266 TWO-YEAR, PLACEBO-CONTROLLED SAFETY AND TOLERABILITY DATA FOR SAFINAMIDE AS ADD-ON TO LEVODOPA IN PATIENTS WITH PARKINSON'S DISEASE (PD)

2.269 SAFINAMIDE AS ADD-ON TO LEVODOPA IN PARKINSON'S DISEASE WITH MOTOR FLUCTUATIONS MAY IMPROVE RESPONDER RATES VERSUS PLACEBO DURING LONG-TERM TREATMENT

P8 Pharmacokinetic/Pharmacodynamics of azithromycin single dose vs three daily doses in a S. pneumoniae or H. influenzae pneumonia model in mice

2-N-Acylaminoalkylindoles: Design and Quantitative Structure−Activity Relationship Studies Leading to MT2-Selective Melatonin Antagonists

P2.098 Saflnamide as an adjunct to levodopa signiflcantly improved motor fluctuations in Parkinson's disease: a phase III, randomized, double-blind, placebo-controlled study

P2.108 Improvements in symptom severity and daily living with saflnamide in Parkinson's disease: a phase III, randomized, double-blind, placebo-controlled study

2.209 Long-term double-blind, placebo-controlled evaluation of the safety and efficacy of safinamide as an add-on to stable dopamine agonist therapy in patients with Parkinson's disease

Twenty-Four-Hour Melatonin and Cortisol Plasma Levels in Relation to Timing of Cluster Headache

Decrease in plasma phenylalanine and tyrosine after phenylalanine-tyrosine free amino acid solutions in man

Abnormal 24-hour urinary excretory pattern of 6-sulphatoxymelatonin in both phases of cluster headache

Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo

Autoradiographic localization of putative melatonin receptors in the brains of two Old World primates: Cercopithecus aethiops and Papio ursinus

Long‐term efficacy and safety of safinamide as add‐on therapy in early P arkinson's disease

Suchergebnisse filtern